GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Beneish M-Score

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Beneish M-Score : 20.89 (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 20.89 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for IPI Legacy Liquidation Co's Beneish M-Score or its related term are showing as below:

IMPLQ' s Beneish M-Score Range Over the Past 10 Years
Min: 15.89   Med: 18.74   Max: 20.89
Current: 20.89

During the past 4 years, the highest Beneish M-Score of IPI Legacy Liquidation Co was 20.89. The lowest was 15.89. And the median was 18.74.


IPI Legacy Liquidation Co Beneish M-Score Historical Data

The historical data trend for IPI Legacy Liquidation Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Beneish M-Score Chart

IPI Legacy Liquidation Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Beneish M-Score
- - - 15.89

IPI Legacy Liquidation Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 15.89 19.94 17.54 20.89

Competitive Comparison of IPI Legacy Liquidation Co's Beneish M-Score

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IPI Legacy Liquidation Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Beneish M-Score falls into.



IPI Legacy Liquidation Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of IPI Legacy Liquidation Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4196+0.528 * 0.8102+0.404 * 61.4016+0.892 * 2.5529+0.115 * 1.3556
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.3892+4.679 * -0.096713-0.327 * 5.5256
=20.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $6.59 Mil.
Revenue was 5.023 + 6.584 + 4.372 + 5.008 = $20.99 Mil.
Gross Profit was 2.793 + 3.364 + 2.087 + 2.79 = $11.03 Mil.
Total Current Assets was $23.43 Mil.
Total Assets was $35.07 Mil.
Property, Plant and Equipment(Net PPE) was $7.82 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.16 Mil.
Selling, General, & Admin. Expense(SGA) was $76.99 Mil.
Total Current Liabilities was $124.74 Mil.
Long-Term Debt & Capital Lease Obligation was $2.24 Mil.
Net Income was -13.814 + -7.357 + -30.067 + -23.041 = $-74.28 Mil.
Non Operating Income was 2.658 + 11.762 + -4.181 + -2.033 = $8.21 Mil.
Cash Flow from Operations was -16.524 + -20.44 + -24.143 + -17.986 = $-79.09 Mil.
Total Receivables was $6.15 Mil.
Revenue was 3.082 + 2.803 + 1.759 + 0.577 = $8.22 Mil.
Gross Profit was 1.574 + 1.066 + 0.726 + 0.136 = $3.50 Mil.
Total Current Assets was $99.28 Mil.
Total Assets was $105.17 Mil.
Property, Plant and Equipment(Net PPE) was $5.71 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.21 Mil.
Selling, General, & Admin. Expense(SGA) was $77.48 Mil.
Total Current Liabilities was $19.96 Mil.
Long-Term Debt & Capital Lease Obligation was $48.95 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.592 / 20.987) / (6.154 / 8.221)
=0.314099 / 0.748571
=0.4196

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.502 / 8.221) / (11.034 / 20.987)
=0.425982 / 0.525754
=0.8102

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (23.427 + 7.817) / 35.073) / (1 - (99.276 + 5.709) / 105.172)
=0.109172 / 0.001778
=61.4016

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=20.987 / 8.221
=2.5529

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.208 / (1.208 + 5.709)) / (1.156 / (1.156 + 7.817))
=0.174642 / 0.128831
=1.3556

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(76.989 / 20.987) / (77.482 / 8.221)
=3.668414 / 9.424887
=0.3892

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.235 + 124.743) / 35.073) / ((48.946 + 19.963) / 105.172)
=3.620392 / 0.655203
=5.5256

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-74.279 - 8.206 - -79.093) / 35.073
=-0.096713

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

IPI Legacy Liquidation Co has a M-score of 20.89 signals that the company is likely to be a manipulator.


IPI Legacy Liquidation Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb officer: CFO 24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin officer: VP, Controller & Interim CFO C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson director 1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams director, officer: COB, CEO and President C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp 10 percent owner 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Headlines